Tuesday, October 4, 2022


Biotechnology News Magazine

Zymo Research Launches COVID-19 Sequencing Service

Latest Posts

Sonrava Health to Include the PreTRM® Test in Its Employee Maternity Benefits Package in Collaboration with Cerebrae and Sera Prognostics

Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and...

BRAINBox Solutions Announces New U.S. Patent Allowance, Strengthening Biomarker Portfolio for Multi-Modal Mild Traumatic Brain Injury Test

BRAINBox Solutions notes the new patent covers both diagnosis of TBI and patient monitoring post-injury, particularly for determining return to work or play.

New Initiative Brings Leading Life Sciences Companies Together To Drive Collective Impact in Awareness, Diagnosis, Care, and Health Equity for Patients with Amyloidosis

Despite notable progress in recent years, amyloidosis patients continue to experience high unmet needs and gaps in treatment and support.

GBS Inc. Acquires Intelligent Fingerprinting Limited and its Proprietary Drugs of Abuse Screening Technology

Steven Boyages, CEO of GBS Inc. stated, “We believe this acquisition generates significant value for our shareholders, and I am extremely excited to be on the forefront of this transition. Bringing IFP under the GBS umbrella marks a significant advancement toward achieving our strategic goals of improving patients’ lives outside of saliva-based glucose testing and laying the pathway in becoming a leader in the development of rapid, non-invasive diagnostic solutions. We remain excited to accelerate our strategy and revenue growth through this collaboration with IFP.”

February 12, 2021

Zymo Research notes this new global service expands Zymo Research’s end-to-end SARS-CoV-2 solutions that include sample collection, RNA extraction, and SARS-CoV-2 detection.

Detecting mutations quickly helps prevent the spread of new viral strain types and can provide an early warning of potential vaccine escape.

Zymo Research, an Illumina-certified sequencing service provider, uses the Illumina COVIDSeq NGS workflow. The end-to-end service includes the necessary collection devices and automated extraction technology, with RNA sequencing completed on Illumina platforms. Zymo Research’s DNA/RNA Shieldis used for the collection, transportation, and preservation of the samples. The preservative inactivates the SARS-CoV-2 virus while stabilizing its RNA, allowing safe room temperature transport for robust library prep and sequencing.

“Zymo Research continues to play a significant role in combating the COVID-19 pandemic,” said Dr. Keith Booher, Leader of Zymo Research Services. “As the SARS-CoV-2 virus mutates, we are committed to developing products and services in our COVID-19 testing portfolio to assist local and federal government laboratories and health organizations in identifying new coronavirus variants of concern, including those recently emerging from the UK (B.1.1.7), South Africa (B.1.351), and Brazil (P.1).”

The COVID-19 Variant Sequencing Service workflow consists of sample collection, processing, sequencing, and reporting. COVID-positive samples are collected from test centers and transported to Zymo Research and its affiliates for processing. Automated RNA extraction from the collected samples is performed using the KingFisher Flex robotics platform. Sequencing is carried out using the Illumina sequencing-by-synthesis technology and then analyzed using the hardware-accelerated DRAGEN COVIDSeq Analysis Pipeline. The final report includes COVID-19 strain identification, genome sequencing coverage, confirmed mutations, consensus genome, and raw sequence files.

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine